# Screening Protocol for Preliminary Eligibility Determination for Adoptive Cell Therapy Trials

> **NCT05100316** · PHASE2 · TERMINATED · sponsor: **GlaxoSmithKline** · enrollment: 16 (actual)

## Conditions studied

- Neoplasms

## Interventions

- **OTHER:** Screening Platform

## Key facts

- **NCT ID:** NCT05100316
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-12-16
- **Primary completion:** 2022-10-04
- **Final completion:** 2022-10-04
- **Target enrollment:** 16 (ACTUAL)
- **Why stopped:** Trial terminated due to feasibility reasons
- **Last updated:** 2024-02-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05100316

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05100316, "Screening Protocol for Preliminary Eligibility Determination for Adoptive Cell Therapy Trials". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05100316. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*